365 related articles for article (PubMed ID: 37268756)
1. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
2. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with
Zhou S; Jiang Y; Luo C; Yuan L
Expert Rev Anticancer Ther; 2024; 24(1-2):59-69. PubMed ID: 38174379
[TBL] [Abstract][Full Text] [Related]
3. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
4. Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
Smith M; Pothuri B
Curr Treat Options Oncol; 2022 Jun; 23(6):887-903. PubMed ID: 35412195
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
6. Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
Gamba T; Paparo J; Panepinto O; Dionisio R; Di Maio M; Vignani F
Clin Genitourin Cancer; 2023 Oct; 21(5):509-516. PubMed ID: 37500375
[TBL] [Abstract][Full Text] [Related]
7. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP; Lacchetti C; Ellis A; Maxian K; Banerjee S; Bookman M; Jones MB; Lee JM; Lheureux S; Liu JF; Moore KN; Muller C; Rodriguez P; Walsh C; Westin SN; Kohn EC
J Clin Oncol; 2020 Oct; 38(30):3468-3493. PubMed ID: 32790492
[TBL] [Abstract][Full Text] [Related]
9. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Gong H; Nie D; Huang Y; Li Z
Int J Gynecol Cancer; 2020 Oct; 30(10):1576-1582. PubMed ID: 32817083
[TBL] [Abstract][Full Text] [Related]
11. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
12. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
13. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
14. Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials.
Ruscito I; Bellati F; Ray-Coquard I; Mirza MR; du Bois A; Gasparri ML; Costanzi F; De Marco MP; Nuti M; Caserta D; Pignata S; Dorigo O; Sehouli J; Braicu EI
Cancer Treat Rev; 2020 Jul; 87():102040. PubMed ID: 32485510
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
Elsea D; Muston D; Fan L; Mihai A; Meng Y; Kasle A; Monberg M
Target Oncol; 2023 Jul; 18(4):531-541. PubMed ID: 37233868
[TBL] [Abstract][Full Text] [Related]
16. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
17. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
Park J; Lim MC; Lee JK; Jeong DH; Kim SI; Choi MC; Kim BG; Lee JY
J Gynecol Oncol; 2022 Mar; 33(2):e12. PubMed ID: 34910393
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials.
Baradács I; Teutsch B; Váradi A; Bilá A; Vincze Á; Hegyi P; Fazekas T; Komoróczy B; Nyirády P; Ács N; Bánhidy F; Lintner B
J Ovarian Res; 2024 Feb; 17(1):53. PubMed ID: 38409030
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer: A Comprehensive Review.
Moore KN; Pothuri B
Cancer J; 2021 Nov-Dec 01; 27(6):432-440. PubMed ID: 34904806
[TBL] [Abstract][Full Text] [Related]
20. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
Maiorano BA; Lorusso D; Maiorano MFP; Ciardiello D; Parrella P; Petracca A; Cormio G; Maiello E
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
